Dezhan Health (000813): The Net Profit Will Drop By 15.55% In 2020, And The Plan Is To Pay 2.1 Yuan For 10 Groups

Dezhan health (000813), which has not paid dividends for many years, disclosed its dividend plan with the financial report on the evening of April 28. In 2020, the company realized a revenue of 963 million yuan, a year-on-year decrease of 45.75%, and a net profit of 285 million yuan, a year-on-year decrease of 15.55%. The total assets of the company are 6.399 billion yuan, and the asset liability ratio is 6.98%. In addition, the company realized a net profit of 64.1819 million yuan in the first quarter of 2021.

At the same time, the company disclosed that in order to guarantee the reasonable investment return of shareholders and consider the capital demand of the company's future development, the company plans to distribute cash dividends of RMB 2.1 (including tax) per 10 shares to all shareholders based on the existing total capital stock of 2.241 billion shares, after deducting 2 million shares of treasury shares that have been repurchased, and 2.239 billion shares with profit distribution rights as the base, A total of 470 million yuan (including tax) was distributed.

Promote new business layout

The main business of Dezhan health company is the research and development, production and sales of drugs. In 2020, Jialin pharmaceutical, a wholly-owned subsidiary of the company, is mainly engaged in the R & D, production and sales of cardiovascular and cerebrovascular drugs. The drugs under production and sale include aroxazole (10mg), AlO (20mg), trimetazidine hydrochloride capsules, fanle tablets type I, fanle tablets II, azathioprine tablets, amiodarone hydrochloride tablets, hydroxyurea tablets and colchicine tablets, Among them, "alo" (general name: atorvastatin calcium tablets) is the core drug variety. The product quality, brand appeal, technical level and production process of "alo" are at the advanced level in the market. It is the first domestic product to pass the consistency evaluation of atorvastatin calcium.

The severe epidemic situation in 2020, the deepening of medical reform, and the continuous expansion of procurement with volume will challenge the operation of the company in 2020. In order to actively respond to the new social, market and industry environment, the company's management vigorously promotes the strategic transformation and upgrading. On the one hand, we should transfer the marketing focus, promote the OTC market promotion, and vigorously develop the OTC market to seek profit recovery through strengthening communication and cooperation with chain customers. On the other hand, it is necessary to actively promote the listing progress of "compound allergol", continuously increase R & D investment, speed up the R & D Progress of innovative drugs, and focus on the transformation of enterprises focusing on innovative drugs.

In addition, the company has actively promoted new business layout in recent years, entering the fields of biological polypeptide products, industrial hemp food and beverage, industrial hemp cosmetics, etc., in order to seek new profit points, and hope to promote the long-term healthy development of the company through multi industry. In 2020, Dezhan health acquired 65% of the shares of HNP and 67% of the shares of hancui bio, and entered the field of biopeptide; It has acquired 51% equity of Shouhui pharmaceutical, becoming one of the three domestic enterprises with vaccine import qualification; Some products in the field of industrial hemp, which began to be cultivated in 2019, have also been officially put on the market.

Through the above-mentioned series of layout and operation, by the end of 2020, the company has formed a pharmaceutical industry as the core, and extended to cover modern industrial hemp and biological polypeptide industries, and its products cover medicine, influenza vaccine, functional drinks, cosmetics and other major health fields.

Deepen OTC market and expand product system

As for the development plan for 2021, Dezhan Health said in the announcement that the company will continue to focus on the "industry + capital" two wheel drive strategy, by adjusting the marketing focus, vigorously develop the OTC market, and tap the potential of "ale" products. At the same time, it will actively promote the listing of new products such as "compound alle", actively play the synergistic effect, and vigorously promote the biological peptide, biological peptide, etc Industrial hemp and other new business development, continuous optimization of the company's product structure, for the company to create a series of new products and profit growth point.

In addition, the company will continue to introduce new heavyweight products and target enterprises with the help of dongfanglue and other channels, implement merger and acquisition strategy, realize rapid expansion, constantly enrich the product pipeline of the company in the fields of anti-tumor, anti-cancer pain, rare diseases and FMCG products, and constantly create new profit growth points. By digging into the original business, actively diversifying the layout, and strengthening the R & D capability, the company will develop into a diversified enterprise with innovative medicine, biological medicine and large health consumption as the core.

It is reported that with the expansion of Alec's procurement with volume, the company's sales target has shifted to the OTC market. With the accumulation of years of market promotion and the influence effect of alo brand, and the perfect sales network established by the company for many years, the company will continue to fully implement the agent mode in 2020, rapidly spread sales in the national OTC market, and cooperate with the agents to complete the transformation of terminal business

At present, Dezhan health has three professional pharmaceutical R & D institutions, which are the Pharmaceutical Biotechnology Research Institute of Jialin pharmaceutical, honghuixin pharmaceutical, and the peptide Biology Research Institute. It has more than 100 experienced full-time R & D personnel with high education, and is responsible for the technical improvement of the company's existing products and the research and development of new drugs.

For the product innovation in 2021, Dezhan Health said that at present, the company has completed the research work of consistency evaluation varieties that have been approved, and re registration of products with 17 varieties and 22 product specifications that have been approved. The company plans to apply for no less than 3 invention patents, and strive to obtain 1-2 authorized invention patents, especially the intellectual property layout related to compound Alain and BRM new drugs, so as to increase the core competitiveness of the company.

At the same time, in the biological peptide sector, the company strives to optimize the process flow, medical and aesthetic projects, and overcome the technical difficulties of human collagen; Establish quality management system of anti-aging project products, upgrade product grade, and promote product listing and production. In the industrial hemp sector, it will also actively promote the research and development of drugs related to industrial hemp, strengthen the marketing team and capacity building of beverage and cosmetics business, focus on promoting live delivery through online channels, improve product exposure, strengthen the layout of offline sales channels, etc., so as to improve product sales.